Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Dec 13:11:208.
doi: 10.1186/1477-7525-11-208.

Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients

Affiliations
Comparative Study

Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients

David A Andrae et al. Health Qual Life Outcomes. .

Abstract

Background: Diarrhea-predominant irritable bowel syndrome (IBS-d) significantly diminishes the health-related quality of life (HRQOL) of patients. Psychological and social impacts are common with many IBS-d patients reporting comorbid depression, anxiety, decreased intimacy, and lost working days. The Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire is a 34-item instrument developed and validated for measurement of HRQOL in non-subtyped IBS patients. The current paper assesses this previously-validated instrument employing data collected from 754 patients who participated in a randomized clinical trial of a novel treatment, eluxadoline, for IBS-d.

Methods: Psychometric methods common to HRQOL research were employed to evaluate the IBS-QOL. Many of the historical analyses of the IBS-QOL validations were used. Other techniques that extended the original methods were applied where more appropriate for the current dataset. In IBS-d patients, we analyzed the items and substructure of the IBS-QOL via item reduction, factor structure, internal consistency, reproducibility, construct validity, and ability to detect change.

Results: This study supports the IBS-QOL as a psychometrically valid measure. Factor analyses suggested that IBS-specific QOL as measured by the IBS-QOL is a unidimensional construct. Construct validity was further buttressed by significant correlations between IBS-QOL total scores and related measures of IBS-d severity including the historically-relevant Irritable Bowel Syndrome Adequate Relief (IBS-AR) item and the FDA's Clinical Responder definition. The IBS-QOL also showed a significant ability to detect change as evidenced by analysis of treatment effects. A minority of the items, unrelated to the IBS-d, performed less well by the standards set by the original authors.

Conclusions: We established that the IBS-QOL total score is a psychometrically valid measure of HRQOL in IBS-d patients enrolled in this study. Our analyses suggest that the IBS-QOL items demonstrate very good construct validity and ability to detect changes due to treatment effects. Furthermore, our analyses suggest that the IBS-QOL items measure a univariate construct and we believe further modeling of the IBS-QOL from an item response theory (IRT) approach under both non-treatment and treatment conditions would greatly further our understanding as item-based methods could be used to develop a short form.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative proportions of patients meeting a certain change from Baseline to Week 12 in IBS-QOL total scores plotted by treatment group.

References

    1. Lovell R, Ford A. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;11:712–721. doi: 10.1016/j.cgh.2012.02.029. - DOI - PubMed
    1. Drossman D. The functional gastrointestinal disorders and the Rome III process. Gastroenterol. 2006;11:1377–1390. doi: 10.1053/j.gastro.2006.03.008. - DOI - PubMed
    1. Drossman D. Rome III The Functional GI Disorders. 3. Lawrence, KS: Allen Press, Inc; 2006.
    1. Brandt L, Chey W, Foxx-Orenstein A. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;11:1–35. - PubMed
    1. Dove L, Lembo A, Randall C, Fogel R, Andrae D, Davenport J, McIntyre G, Almenoff J, Covington P. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013;11:329–338. doi: 10.1053/j.gastro.2013.04.006. - DOI - PubMed

Publication types

MeSH terms